Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 21-32 , March 2010

An overview of chronic lymphocytic leukaemia biology

  • M.T.S. Bertilaccio, PhD

      Affiliations

    • Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • Tel.: +390226434969; fax +390226434575. bertilaccio.sabrina@hsr.it
    • ,
  • C. Scielzo, PhD

      Affiliations

    • Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • Università degli Studi di Milano, Via Mangiagalli 31 20133, Milano, Italy
    • Tel.: +390226437104; fax +390226434575. scielzo.cristina@hsr.it
    • ,
  • M. Muzio, PhD

      Affiliations

    • Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • Tel.: +390226437104; fax: +390226434575. muzio.marta@hsr.it
    • ,
  • F. Caligaris-Cappio (Professor)

      Affiliations

    • Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
    • Università Vita-Salute San Raffaele, Via Olgettina 58 20132 Milano, Italy
    • Corresponding Author InformationCorresponding author. Università Vita-Salute San Raffaele, Via Olgettina 58, 20132, Milan, Italy. Tel.: +39 02 2643 2390; fax: +39 02 2643 4795.

References 

  1. Ghia P, Caligaris-Cappio F. The origin of B-cell chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2):150–156
  2. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001 Dec 3;194(11):1625–1638
  3. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002 Jun 1;99(11):4087–4093
  4. Freedman AS, Boyd AW, Bieber FR, Daley J, Rosen K, Horowitz JC, et al. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood. 1987 Aug;70(2):418–427
  5. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med. 1982 Feb 1;155(2):623–628
  6. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008 Sep 1;112(5):1570–1580
  7. Forster I, Rajewsky K. Expansion and functional activity of Ly-1 + B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice. Eur J Immunol. 1987 Apr;17(4):521–528
  8. Ansel KM, Harris RB, Cyster JG. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity. 2002 Jan;16(1):67–76
  9. Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity. 2005 Jul;23(1):7–18
  10. Forster I, Gu H, Muller W, Schmitt M, Tarlinton D, Rajewsky K. CD5 B cells in the mouse. Curr Top Microbiol Immunol. 1991;173:247–251
  11. Stall AM, Farinas MC, Tarlinton DM, Lalor PA, Herzenberg LA, Strober S, et al. Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7312–7316
  12. LeMaoult J, Delassus S, Dyall R, Nikolic-Zugic J, Kourilsky P, Weksler ME. Clonal expansions of B lymphocytes in old mice. J Immunol. 1997 Oct 15;159(8):3866–3874
  13. Kantor A. A new nomenclature for B cells. Immunol Today. 1991 Nov;12(11):388
  14. Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today. 1999 Jul;20(7):312–316
  15. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841–894
  16. Wortis HH, Teutsch M, Higer M, Zheng J, Parker DC. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3348–3352
  17. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004 Jun 15;103(12):4389–4395
  18. Stilgenbauer S, Lichter P, Dohner H. Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000 Mar;4(1):48–72
  19. Caligaris-Cappio FROMA. illuminates CLL genomic lesions. Blood. 2009 Feb 5;113(6):1209–1210
  20. Grubor V, Krasnitz A, Troge JE, Meth JL, Lakshmi B, Kendall JT, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood. 2009 Feb 5;113(6):1294–1303
  21. Stilgenbauer S, Dohner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am. 2004 Aug;18(4):827–848viii
  22. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524–15529
  23. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944–13949
  24. Ruzzene M, Brunati AM, Sarno S, Marin O, Donella-Deana A, Pinna LA. Ser/Thr phosphorylation of hematopoietic specific protein 1 (HS1): implication of protein kinase CK2. Eur J Biochem. 2000 May;267(10):3065–3072
  25. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009 Jul 27;
  26. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C, et al. In vivo intra- and inter-clonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood. 2009 Sep 29;
  27. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol. 2003 Nov;123(3):380–388
  28. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004 Aug 16;200(4):519–525
  29. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000 Oct 15;96(8):2655–2663
  30. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Sep 17;
  31. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood. 2003 Sep 15;102(6):2146–2155
  32. Chiorazzi N, Hatzi K, Albesiano E. B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci. 2005 Dec;1062:1–12
  33. Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006 May 1;107(9):3584–3592
  34. Stark RS, Liebes LF, Shelanski ML, Silber R. Anomalous function of vimentin in chronic lymphocytic leukemia lymphocytes. Blood. 1984 Feb;63(2):415–420
  35. Caligaris-Cappio F, Bergui L, Tesio L, Corbascio G, Tousco F, Marchisio PC. Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia and hairy cell leukemia. Blood. 1986 Jan;67(1):233–239
  36. Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, et al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol. 2009 Apr 10;27(11):1844–1849
  37. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008 Jul;118(7):2427–2437
  38. Vicente-Manzanares M, Sanchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat Rev Immunol. 2004 Feb;4(2):110–122
  39. Hao JJ, Zhu J, Zhou K, Smith N, Zhan X. The coiled-coil domain is required for HS1 to bind to F-actin and activate Arp2/3 complex. J Biol Chem. 2005 Nov 11;280(45):37988–37994
  40. Muzio M, Scielzo C, Frenquelli M, Bachi A, De Palma M, Alessio M, et al. HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells. Leukemia. 2007 May 17;
  41. Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD. LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity. 2004 May;20(5):589–599
  42. Fleire SJ, Goldman JP, Carrasco YR, Weber M, Bray D, Batista FD. B cell ligand discrimination through a spreading and contraction response. Science. 2006 May 5;312(5774):738–741
  43. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007 Dec 1;110(12):4012–4021
  44. Scielzo C, Ghia P, Conti A, Bachi A, Guida G, Geuna M, et al. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest. 2005 Jun;115(6):1644–1650
  45. Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res. 2009 Apr 1;69(7):3121–3130
  46. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1848–1854
  47. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007 Jan 1;109(1):259–270
  48. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26;351(9):893–901
  49. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003 May 1;348(18):1764–1775
  50. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood. 2000 Apr 1;95(7):2455–2457
  51. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, Huttmann A, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 2002 Jan;16(1):30–35
  52. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood. 1996 Aug 15;88(4):1365–1374
  53. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia. 2006 Apr;20(4):689–695
  54. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15;100(13):4609–4614
  55. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003 Feb 1;101(3):1087–1093
  56. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007 Nov 1;110(9):3352–3359
  57. Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani AA, et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood. 2007 Jun 15;109(12):5390–5398
  58. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005 Nov 7;202(9):1171–1177
  59. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006 Mar 20;203(3):553–561
  60. Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol. 2007 Jun;19(3):268–274
  61. Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris-Cappio F. The role of Toll-like receptors in chronic B cell malignancies. Leuk Lymphoma. 2009 Aug 11;1–8
  62. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature. 1989 Dec 21–28;342(6252):929–931
  63. Buske C, Gogowski G, Schreiber K, Rave-Frank M, Hiddemann W, Wormann B. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp Hematol. 1997 Apr;25(4):329–337
  64. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001 May 1;97(9):2777–2783
  65. Granziero L, Circosta P, Scielzo C, Frisaldi E, Stella S, Geuna M, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5 + B lymphocytes. Blood. 2003 Mar 1;101(5):1962–1969
  66. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993 Apr 1;177(4):925–935
  67. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999 Sep;106(4):995–1004
  68. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997 May;97(2):409–417
  69. Pizzolo G, Chilosi M, Ambrosetti A, Semenzato G, Fiore-Donati L, Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood. 1983 Dec;62(6):1289–1296
  70. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003 Feb 15;101(4):1262–1269
  71. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002 Nov 15;100(10):3741–3748
  72. Sainz-Perez A, Gary-Gouy H, Portier A, Davi F, Merle-Beral H, Galanaud P, et al. High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia. Leukemia. 2006 Mar;20(3):498–504
  73. Gauld SB, Dal Porto JM, Cambier J. B Cell Antigen Receptor Sci STKE (Connections Map Pathway). Avaliable at: http://stke.sciencemag.org/cgi/cm/stkecm;CMP_69092002;
  74. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007 Jan;21(1):110–120
  75. Rodriguez A, Martinez N, Camacho FI, Ruiz-Ballesteros E, Algara P, Garcia JF, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res. 2004 Oct 15;10(20):6796–6806
  76. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005 Feb;115(2):369–378
  77. Schuh K, Avots A, Tony HP, Serfling E, Kneitz C. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma. 1996 Nov;23(5-6):583–592
  78. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000 Feb 15;164(4):2200–2206
  79. Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008 Jul 1;112(1):188–195
  80. Merrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, et al. Identification of anergic B cells within a wild-type repertoire. Immunity. 2006 Dec;25(6):953–962
  81. Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity. 1997 Apr;6(4):419–428
  82. Wong SC, Chew WK, Tan JE, Melendez AJ, Francis F, Lam KP. Peritoneal CD5 + B-1 cells have signaling properties similar to tolerant B cells. J Biol Chem. 2002 Aug 23;277(34):30707–30715
  83. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol. 2005 Nov;6(11):1160–1167
  84. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007 Jan 25;
  85. Phillips JA, Mehta K, Fernandez C, Raveche ES. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res. 1992 Jan 15;52(2):437–443
  86. Brunati AM, Ruzzene M, James P, Guerra B, Pinna LA. Hierarchical phosphorylation of a 50-kDa protein by protein tyrosine kinases TPK-IIB and C-Fgr, and its identification as HS1 hematopoietic-lineage cell-specific protein. Eur J Biochem. 1995 Apr 1;229(1):164–170
  87. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024–7029
  88. Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood. 2007 Mar 9;
  89. Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H, et al. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther. 2009 Sep;8(9):2684–2692
  90. Wen X, Zhang D, Kikuchi Y, Jiang Y, Nakamura K, Xiu Y, et al. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur J Immunol. 2004 Oct;34(10):2740–2749
  91. Scaglione BJ, Salerno E, Balan M, Coffman F, Landgraf P, Abbasi F, et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol. 2007 Dec;139(5):645–657
  92. Zapata JM, Krajewska M, Morse HC, Choi Y, Reed JC. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600–16605
  93. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. 2006 Jul;118(3):281–292
  94. Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gomez-Caro R, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell. 2004 Oct;6(4):399–408
  95. Pekarsky Y, Zanesi N, Aqeilan RI, Croce CM. Animal models for chronic lymphocytic leukemia. J Cell Biochem. 2007 Apr 1;100(5):1109–1118
  96. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955–6960
  97. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11713–11718
  98. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006 Aug 15;108(4):1334–1338
  99. Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol. 2009 Jun 1;182(11):6771–6778
  100. Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood. 2009 Mar 19;113(12):2791–2794
  101. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J, et al. Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell-turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Sep 15;
  102. ter Brugge PJ, Ta VB, de Bruijn MJ, Keijzers G, Maas A, van Gent DC, et al. A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood. 2009 Jul 2;114(1):119–127
  103. Hummel JL, Lichty BD, Reis M, Dube I, Kamel-Reid S. Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia. 1996 Aug;10(8):1370–1376
  104. Shimoni A, Marcus H, Dekel B, Shkarchi R, Arditti F, Shvidel L, et al. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human–>mouse radiation chimera. Cancer Res. 1999 Dec 1;59(23):5968–5974
  105. Durig J, Ebeling P, Grabellus F, Sorg UR, Mollmann M, Schutt P, et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res. 2007 Sep 15;67(18):8653–8661
  106. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999 Feb;23(2):127–136
  107. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005 Mar;115(3):755–764

PII: S1521-6926(09)00106-6

doi: 10.1016/j.beha.2009.12.005

Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 21-32 , March 2010

Article Tools

* Image Usage & Resolution